At the news
? BEARISHIMPACT 6/10 8-K filed Nov 12, 2026 at 16:01 ET
Arrowhead Pharmaceuticals reported fiscal 2026 full-year revenue of $450.8M, down 45.6% from $829.4M in fiscal 2025, and a GAAP net loss of $724.2M ($5.11 per share) versus a $1.6M loss in the prior year. The revenue decline was driven by the absence of large upfront licensing fees that boosted fiscal 2025, while operating expenses rose sharply due to a $215M priority review voucher acquisition and higher R&D and SG&A costs. The company highlighted strong REDEMPLO commercial momentum, FDA STAR program entry for the sHTG sNDA, and positive clinical data across multiple pipeline programs.
- Fiscal 2026 revenue $450.8M, down 45.6% from $829.4M in fiscal 2025.
- GAAP net loss attributable to Arrowhead of $724.2M ($5.11 per diluted share) versus a $1.6M loss in fiscal 2025.
- Operating expenses rose to $1.158B from $731.1M, including a $215M acquired priority review voucher.
- Total cash resources (cash, equivalents, and securities) were $1.193B at September 30, 2026, up from $919.4M a year earlier.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access